Chlorotoxin-conjugated onconase as a potential anti-glioma drug

Wang,Xiaomin; Guo,Zhanyun

doi:10.3892/ol.2014.2835

Chlorotoxin-conjugated onconase as a potential anti-glioma drug

Authors:
- Xiaomin Wang
- Zhanyun Guo
View Affiliations

Affiliations: Institute of Protein Research, College of Life Sciences and Technology, Tongji University, Shanghai 200092, P.R. China
Published online on: December 29, 2014 https://doi.org/10.3892/ol.2014.2835
Pages: 1337-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas are rarely curable malignant brain tumors arising from normal glial cells. The scorpion‑derived small peptide, chlorotoxin (CTX), can selectively bind malignant gliomas. In the present study, a CTX‑conjugated onconase (Onc), a small cytotoxic ribonuclease, was prepared as a potential anti‑glioma drug. In this conjugate, recombinant CTX was covalently linked with recombinant Onc by reversible disulfide linkage. The chemically conjugated CTX‑Onc showed much higher cytotoxicity to the cultured glioma U251 and SHG‑44 cells than the physical mixture of CTX and Onc (CTX + Onc). In the nude mouse models bearing subcutaneous U251 or SHG‑44 tumors, the CTX‑Onc conjugate also showed improved anti‑tumor effects than the CTX + Onc control. These results suggested that the reversible chemical‑conjugated CTX promoted the tumor targeting of Onc, and thus the present CTX‑Onc conjugate could be further developed as a potential targeted anti‑glioma drug.

View Figures

View References

1	Tanaka S, Louis DN, Curry WT, Batchelor TT and Dietrich J: Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 10:14–26. 2013. View Article : Google Scholar
2	Watkins S and Sontheimer H: Unique biology of gliomas: challenges and opportunities. Trends Neurosci. 35:546–556. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lima FR, Kahn SA, Soletti RC, et al: Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta. 1826:338–349. 2012.PubMed/NCBI
4	Patel M, Vogelbaum MA, Barnett GH, et al: Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs. 21:1247–1266. 2012. View Article : Google Scholar : PubMed/NCBI
5	Polivka J Jr, Polivka J, Rohan V, Topolcan O and Ferda J: New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res. 32:2935–2946. 2012.PubMed/NCBI
6	Agarwal S, Sane R, Oberoi R, Ohlfest JR and Elmquist WF: Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 13:e172011. View Article : Google Scholar : PubMed/NCBI
7	Soroceanu L, Gillespie Y, Khazaeli MB and Sontheimer H: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. 58:4871–4879. 1998.PubMed/NCBI
8	Lyons SA, O’Neal J and Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 39:162–173. 2002. View Article : Google Scholar : PubMed/NCBI
9	Deshane J, Garner CC and Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 278:4135–4144. 2003. View Article : Google Scholar
10	Kesavan K, Ratliff J, Johnson EW, et al: Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem. 285:4366–4374. 2010. View Article : Google Scholar :
11	DeBin JA, Maggio JE and Strichartz GR: Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol. 264:C361–C369. 1993.PubMed/NCBI
12	Veiseh M, Gabikian P, Bahrami SB, et al: Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 67:6882–6888. 2007. View Article : Google Scholar : PubMed/NCBI
13	Sun C, Veiseh O, Gunn J, et al: In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small. 4:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sun C, Fang C, Stephen Z, et al: Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond). 3:495–505. 2008. View Article : Google Scholar
15	Veiseh O, Kievit FM, Gunn JW, Ratner BD and Zhang M: A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials. 30:649–657. 2009. View Article : Google Scholar :
16	Veiseh O, Gunn JW, Kievit FM, et al: Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small. 5:256–264. 2009. View Article : Google Scholar :
17	Orndorff RL and Rosenthal SJ: Neurotoxin quantum dot conjugates detect endogenous targets expressed in live cancer cells. Nano Lett. 9:2589–2599. 2009. View Article : Google Scholar : PubMed/NCBI
18	Veiseh O, Sun C, Fang C, et al: Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69:6200–6207. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kievit FM, Veiseh O, Fang C, et al: Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano. 4:4587–4594. 2010. View Article : Google Scholar : PubMed/NCBI
20	Huang R, Han L, Li J, et al: Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis. Biomaterials. 32:5177–5186. 2011. View Article : Google Scholar : PubMed/NCBI
21	Fu Y, An N, Li K, Zheng Y and Liang A: Chlorotoxin-conjugated nanoparticles as potential glioma-targeted drugs. J Neurooncol. 107:457–462. 2012. View Article : Google Scholar
22	Cheng Y, Zhao J, Qiao W and Chen K: Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging. 4:385–405. 2014.PubMed/NCBI
23	Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet. 21:169–182. 1988.PubMed/NCBI
24	Ardelt W, Mikulski SM and Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem. 266:245–251. 1991.PubMed/NCBI
25	Mosimann SC, Ardelt W and James MN: Refined 1.7 A X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol. 236:1141–1153. 1994. View Article : Google Scholar : PubMed/NCBI
26	Wu Y, Mikulski SM, Ardelt W, Rybak SM and Youle RJ: A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem. 268:10686–10693. 1993.PubMed/NCBI
27	Saxena SK, Sirdeshmukh R, Ardelt W, et al: Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem. 277:15142–15146. 2002. View Article : Google Scholar : PubMed/NCBI
28	Suhasini AN and Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 281:12201–12209. 2006. View Article : Google Scholar : PubMed/NCBI
29	Rodríguez M, Torrent G, Bosch M, et al: Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci. 120:1405–1411. 2007. View Article : Google Scholar : PubMed/NCBI
30	Newton DL, Hansen HJ, Mikulski SM, et al: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood. 97:528–535. 2001. View Article : Google Scholar : PubMed/NCBI
31	Pavlakis N and Vogelzang NJ: Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 6:391–399. 2006. View Article : Google Scholar : PubMed/NCBI
32	Lee I, Kalota A, Gewirtz AM and Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 27:299–307. 2007.PubMed/NCBI
33	Chang CH, Gupta P, Michel R, et al: Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther. 9:2276–2286. 2010. View Article : Google Scholar : PubMed/NCBI
34	Wang XM, Luo X and Guo ZY: Recombinant expression and downstream processing of the disulfide-rich tumor-targeting peptide chlorotoxin. Exp Ther Med. 6:1049–1053. 2013.PubMed/NCBI
35	Wang XM and Guo ZY: Recombinant expression, different downstream processing of the disulfide-rich anti-tumor peptide Ranpirnase and its effect on the growth of human glioma cell line SHG-44. Biomed Rep. 1:747–750. 2013.
36	Hockaday DC, Shen S, Fiveash J, et al: Imaging glioma extent with 131I-TM-601. J Nucl Med. 46:580–586. 2005.PubMed/NCBI
37	Pavlakis N and Vogelzang NL: Ranpirnase-an antitumor ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Therm. 6:391–399. 2006. View Article : Google Scholar
38	Xiang Y, Liang L, Wang X, et al: Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release. 152:402–410. 2011. View Article : Google Scholar : PubMed/NCBI